Metformin and polycystic ovary syndromeLebinger, Tessa GCurrent Opinion in Endocrinology, Diabetes and Obesity: April 2007 - Volume 14 - Issue 2 - p 132–140 doi: 10.1097/MED.0b013e328089f0ea Diabetes and the endocrine pancreas Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The aim of this article is to describe the role of insulin resistance in the etiology of polycystic ovary syndrome and to review the results of treatment with the insulin sensitizing drug metformin. Recent findings Polycystic ovary syndrome is a heterogeneous combination of clinical, hormonal, and reproductive abnormalities associated with insulin resistance and increased cardiovascular risk factors. Reduction of hyperinsulinism and improvement of insulin sensitivity with metformin has been reported to ameliorate these abnormalities in many, but not all studies, with few adverse effects. Summary Metformin may be the drug of first choice for most, if not all women with polycystic ovarian syndrome, either alone or in combination with other treatments. Further investigation is necessary to determine the optimal dose and duration of treatment necessary to maximize response. Department of Pediatrics, New York Medical College, Valhalla, New York, USA Correspondence to Tessa G. Lebinger, MD, 121 Bon Air Ave, New Rochelle, NY 10804, USA E-mail: Lebingert@alum.mit.edu © 2007 Lippincott Williams & Wilkins, Inc.